Tracking the impact of translational research in psychiatry: state of the art and perspectives

被引:28
作者
Machado-Vieira, Rodrigo [1 ]
机构
[1] Univ Sao Paulo, Inst & Dept Psychiat, Neurosci Lab, LIM27, Sao Paulo, Brazil
来源
JOURNAL OF TRANSLATIONAL MEDICINE | 2012年 / 10卷
关键词
Translational; Psychiatry; Personalized; Treatment; Human; Animal; Research; Biomarker; SURROGATE END-POINTS; DRUG DISCOVERY; ANIMAL-MODELS; MEDICINE; ANTIDEPRESSANT; BIOMARKERS; DISORDER; PHARMACOGENOMICS; SCHIZOPHRENIA; VALIDATION;
D O I
10.1186/1479-5876-10-175
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Personalized treatments have become a primary goal in translational psychiatric research. They include the identification of neural circuits associated with psychiatric disorders and definition of treatment according to individual characteristics. Many new tools and technologies have been developed but further efforts are required to provide clues on how these scientific advances in psychiatry may be translated into more effective therapeutic approaches. Obstacles to the progress of translational psychiatry also involve numerous scientific, financial, ethical, logistics and regulatory aspects. Also, the goal of DSM-5 to expand "signs and symptoms" classification to incorporate biological measures may help the development of new multifactorial and dimensional models able to better understand the pathophysiology of psychiatric disorders and develop improved treatments. Finally, a better understanding on the significant response variability, cognitive functioning, role of comorbidities and treatment-resistant cases are critical for the development of prevention and intervention strategies that are more effective.
引用
收藏
页数:7
相关论文
共 31 条
[11]  
Gilles Christian, 2002, Dialogues Clin Neurosci, V4, P377
[12]   The endophenotype concept in psychiatry: Etymology and strategic intentions [J].
Gottesman, II ;
Gould, TD .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (04) :636-645
[13]   Neurokinin-l receptor antagonists as novel antidepressants: trials and tribulations [J].
Hafizi, Sepehr ;
Chandra, Prakash ;
Cowen, Philip J. .
BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 :282-284
[14]   Future drug discovery and development [J].
Hurko, Orest .
MOLECULAR GENETICS AND METABOLISM, 2010, 100 :S92-S96
[15]   The Uses of Biomarkers in Drug Development [J].
Hurko, Orest .
BIOMARKERS IN BRAIN DISEASE, 2009, 1180 :1-10
[16]   Translating Scientific Opportunity Into Public Health Impact A Strategic Plan for Research on Mental Illness [J].
Insel, Thomas R. .
ARCHIVES OF GENERAL PSYCHIATRY, 2009, 66 (02) :128-133
[17]   Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial [J].
Keefe, Richard S. E. ;
Fox, Kolleen Hurley ;
Harvey, Philip D. ;
Cucchiaro, Josephine ;
Siu, Cynthia ;
Loebel, Antony .
SCHIZOPHRENIA RESEARCH, 2011, 125 (2-3) :161-168
[18]   Can the pharmaceutical industry reduce attrition rates? [J].
Kola, I ;
Landis, J .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :711-715
[19]   A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study [J].
Koychev, Ivan ;
McMullen, Katrina ;
Lees, Jane ;
Dadhiwala, Rukiya ;
Grayson, Lois ;
Perry, Charlotte ;
Schmechtig, Anne ;
Walters, James ;
Craig, Kevin J. ;
Dawson, Gerard R. ;
Dourish, Colin T. ;
Ettinger, Ulrich ;
Wilkinson, Lawrence ;
Williams, Steven ;
Deakin, John Francis William ;
Barkus, Emma .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 (07) :469-481
[20]   What's next in translational medicine? [J].
Littman, Bruce H. ;
Di Mario, Linda ;
Plebani, Mario ;
Marincola, Francesco M. .
CLINICAL SCIENCE, 2007, 112 (3-4) :217-227